Newtown-based Traws Pharma, Inc. revealed that the anticipated Phase 2a human influenza challenge study involving tivoxavir marboxil (TXM) has been postponed. This decision follows a discouraging evaluation by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA). Traws Pharma, Inc., listed as TRAW on NASDAQ, specializes in pioneering therapies for global viral threats. The company had high hopes for TXM, but setbacks have caused a delay in the clinical trial process. The MHRA's review results have led to a disruption in the development timeline for this crucial study.